Drusolv Therapeutics, Inc.

About

is a clinical-stage drug company focused on development of a repurposed, very high-dose statin for early intervention in a blinding eye disease called age-related macular degeneration (AMD). There are currently 9.5 million cases of dry, early-stage AMD in the US and Canada. There is no effective therapy for onset of early “dry” AMD.